| Dr Julianne Rebecca Biroschak, MD | |
|
644 W Putnam Ave, Greenwich, CT 06830 | |
| (203) 210-2880 | |
| (203) 210-2881 |
| Full Name | Dr Julianne Rebecca Biroschak |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 15 Years |
| Location | 644 W Putnam Ave, Greenwich, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689800104 | NPI | - | NPPES |
| 008080567 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 060485 (Connecticut) | Secondary |
| 207V00000X | Obstetrics & Gynecology | 269608 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Greenwich Hospital Association - | Greenwich, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Westchester Medical Group Pc | 6406752963 | 405 |
| Westchester Medical Group Pc | 6406752963 | 405 |
News Archive
Viora is excited to announce that its popular "Rent-to-Own" program for Reaction™ will now be offered in Canada to medical aesthetic practitioners. Now Canadian physicians will have the ability to introduce the leading medical aesthetic device for body contouring and skin tightening into their practice at minimal risk - with no capital investment, no financing, and no long term commitment.
Research presented today at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) indicated that a patient's race may play a role in the success of their infertility treatment.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
› Verified 9 days ago
| Entity Name | Westchester Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881653822 PECOS PAC ID: 6406752963 Enrollment ID: O20031208000533 |
News Archive
Viora is excited to announce that its popular "Rent-to-Own" program for Reaction™ will now be offered in Canada to medical aesthetic practitioners. Now Canadian physicians will have the ability to introduce the leading medical aesthetic device for body contouring and skin tightening into their practice at minimal risk - with no capital investment, no financing, and no long term commitment.
Research presented today at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) indicated that a patient's race may play a role in the success of their infertility treatment.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
› Verified 9 days ago
| Entity Name | Icahn School Of Medicine At Mount Sinai |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124392212 PECOS PAC ID: 2264691070 Enrollment ID: O20120910000003 |
News Archive
Viora is excited to announce that its popular "Rent-to-Own" program for Reaction™ will now be offered in Canada to medical aesthetic practitioners. Now Canadian physicians will have the ability to introduce the leading medical aesthetic device for body contouring and skin tightening into their practice at minimal risk - with no capital investment, no financing, and no long term commitment.
Research presented today at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) indicated that a patient's race may play a role in the success of their infertility treatment.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Julianne Rebecca Biroschak, MD 2700 Westchester Ave, Purchase, NY 10577-2547 Ph: (914) 607-5730 | Dr Julianne Rebecca Biroschak, MD 644 W Putnam Ave, Greenwich, CT 06830 Ph: (203) 210-2880 |
News Archive
Viora is excited to announce that its popular "Rent-to-Own" program for Reaction™ will now be offered in Canada to medical aesthetic practitioners. Now Canadian physicians will have the ability to introduce the leading medical aesthetic device for body contouring and skin tightening into their practice at minimal risk - with no capital investment, no financing, and no long term commitment.
Research presented today at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) indicated that a patient's race may play a role in the success of their infertility treatment.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."
Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, Indiana University Bloomington scientists report in this month's Cancer Biology & Therapy.
› Verified 9 days ago
Linda M Reid, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 644 W Putnam Ave, Greenwich, CT 06830 Phone: 203-210-2880 Fax: 203-210-2881 | |
Dr. Patricia Eillen Palos, Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2 1/2 Dearfield Dr, Suite 101, Greenwich, CT 06831 Phone: 203-861-9586 Fax: 203-861-9587 | |
Jeff G Wang, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 100 Putnam Grn, Greenwich, CT 06830 Phone: 203-774-9900 | |
Masahide D Kanayama, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 4 Dearfield Dr, Greenwich, CT 06831 Phone: 203-422-0477 Fax: 203-661-1607 | |
Juliet Mushi, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5 Perryridge Rd, Greenwich, CT 06830 Phone: 203-863-3972 Fax: 203-863-4647 | |
Miss Alicia Isabel Robbins, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1 E Putnam Ave Fl Ll, Greenwich, CT 06830 Phone: 203-935-8454 | |
Barry Witt, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 55 Holly Hill Ln Ste 270, Greenwich, CT 06830 Phone: 032-863-2990 |